Maharashtra FDA targets Vimal surrogate ads in wider food-safety enforcement drive
Maharashtra’s food regulator has asked Shah Rukh Khan, Ajay Devgn and Tiger Shroff to stop appearing in Vimal cardamom ads linked to banned pan masala, giving them 15 days to respond. The broader drive also shut four Domino’s stores and 12 grocery warehouses.
What happened
Maharashtra FDA ordered Shah Rukh Khan, Ajay Devgn and Tiger Shroff to stop Vimal cardamom surrogate ads linked to banned pan masala, amid a wider food-safety
Key facts
- Three Bollywood actors warned
- 15 days to respond
- 4 Domino's stores shut
- 12 grocery warehouses shut
- Pan masala market estimated at $5 billion last year
- Pan masala packs priced at Rs 3.5
- Vimal cardamom ad has 106 million YouTube views
Why this matters
Apply deeper regulatory, advertising-linkage and food-safety diligence to FMCG and food-service targets, especially businesses reliant on surrogate branding or fragmented operating compliance.
What to watch
- Whether the named celebrities respond, withdraw, or face penalties after the 15-day notice window.
- Any Maharashtra FDA order against Vimal entities, ad agencies, broadcasters, digital platforms or retailers.
- Copycat notices from other state FDAs, CCPA, ASCI, Ministry of Information and Broadcasting or health authorities.
- Expansion of Domino's closures or enforcement actions against other national QSR chains and grocery/dark-store operators.
- Evidence that enforcement includes warehouse hygiene, expired inventory, labeling, adulteration or licensing violations rather than isolated cases.
- Freeze or legally re-review surrogate campaigns, celebrity endorsements, packaging and point-of-sale creative.
- Run rapid compliance audits across warehouses, franchise kitchens, cold-chain records, labeling, licenses and pest-control documentation.
- Prepare crisis-response plans separating compliant FMCG products from restricted pan masala or tobacco-linked brand associations.
- Increase supplier and franchisee inspection frequency, with corrective-action evidence ready for regulators.
- Shift marketing spend toward product-specific, non-surrogate campaigns and lower-regulatory-risk channels.